Pliant Therapeutics PLRX 深 滬
等待開盤 09-18 09:30:00 美东时间
1.46
-0.070
-4.58%
華盛通- 最 高1.54
- 今 開1.54
- 成交量 53.48万股
- 最 低 1.45
- 昨 收 1.53
- 總市值 8962.68万
- 52周最高 16.10
- 市盈率 靜 --
- 換手率 0.87%
- 52周最低 1.1001
- 委 比 76.48%
- 總股本 6138.82万
- 歷史最高 43.92
- 量 比 1.44
- 振 幅 5.88%
- 歷史最低 1.1001
- 每 手 1
- 風險率 5.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pliant Therapeutics Q2 EPS $(0.71), Inline
Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.71) per share which met the analyst consensus estimate. This is a 22.83 percent increase over losses of $(0.92) per share from the same period last year.
08-08 04:56
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Pliant Therapeutics has halted development of bexotegrast in idiopathic pulmonary fibrosis (IPF) following a safety and efficacy analysis. The company continues Phase 1 trials of PLN-101095 in solid tumors, expecting data by year-end. Restructuring efforts to reduce costs have largely been completed, with decreases in R&D and general expenses. As of June 2025, the company held $264.4 million in cash. Pliant remains focused on advancing integrin-b...
08-07 20:05
Pliant ends development of idiopathic pulmonary fibrosis asset bexotegrast
Pliant Therapeutics is ending development of idiopathic pulmonary fibrosis candidate bexotegrast following poor phase 2b/3 results. In March, the company ended the BEACON-IPF trial following a Data Sa...
06-28 04:32
Pliant Therapeutics Discontinues Development Of Bexotegrast In Idiopathic Pulmonary Fibrosis After BEACON-IPF Phase 2b/3 Clinical Trial Review
Bexotegrast development in IPF discontinuedClinical oncology program and early-stage programs continueRecent workforce and operational changes align with next stepsSOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE
06-28 04:12
Pliant Therapeutics Provides Update on BEACON-IPF
Pliant Therapeutics announced the discontinuation of bexotegrast development in idiopathic pulmonary fibrosis (IPF) following unfavorable safety and efficacy results from the BEACON-IPF Phase 2b/3 trial. While the drug showed modest improvements in lung function, it posed increased risks of disease progression and adverse events. The company is focusing on its oncology program, with PLN-101095 entering Phase 1 trials, and leveraging its proprieta...
06-27 20:05
Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside
Tvardi advances fibrosis drug TTI-101 in IPF and liver cancer as Piper initiates with $78 target; merger boosts cash runway into late 2026.
06-13 03:08
Pliant Therapeutics Q1 EPS $(0.92) Misses $(0.74) Estimate
Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.74) by 24.32 percent. This is a 17.95 percent decrease over losses of $(0.78) per share
05-09 05:03
Pliant Therapeutics to trim about 45% of workforce
Pliant Therapeutics (NASDAQ:PLRX) said on Friday that it will cut approximately 45% of its current workforce, across all departments, amid the company's recent restructuring measures. The company will...
05-02 22:27
HC Wainwright & Co. Reiterates Neutral on Pliant Therapeuticsto Neutral
HC Wainwright & Co. analyst Ed Arce reiterates Pliant Therapeutics (NASDAQ:PLRX) from Neutral to Neutral.
03-18 23:53
Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types
Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested in its Phase 1 trial.
03-18 01:39
